Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer

European Journal of Cancer

Volumn 49, Issue 14, 2013, Pages 3003-3009

  Kawakami, Hisato ^a   Okamoto, Isamu ^a,b   Hayashi, Hidetoshi ^a   Taguri, Masataka ^c   Morita, Satoshi ^c   Nakagawa, Kazuhiko ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYUSHU UNIVERSITY HOSPITAL   (Japan)

^c YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

Chemotherapy; Clinical trial; Gastric cancer; Overall survival; Progression free survival

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; HUMAN; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH CANCER;

CHEMOTHERAPY; CLINICAL TRIAL; GASTRIC CANCER; OVERALL SURVIVAL; PROGRESSION-FREE SURVIVAL;

CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOMACH NEOPLASMS; TIME FACTORS;

EID: 84883053473     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.05.022     Document Type: Article

References (25)

1. A. Jemal, F. Bray, and M.M. Center Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. A.M. Murad, F.F. Santiago, and A. Petroianu Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer Cancer 72 1993 37 41
3. B. Glimelius, K. Hoffman, and U. Haglund Initial or delayed chemotherapy with best supportive care in advanced gastric cancer Ann Oncol 5 1994 189 190
4. S. Pyrhonen, T. Kuitunen, and P. Nyandoto Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer Br J Cancer 71 1995 587 591
5. E. Van Cutsem, V.M. Moiseyenko, and S. Tjulandin Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group J Clin Oncol 24 2006 4991 4997
6. D. Cunningham, N. Starling, and S. Rao Capecitabine and oxaliplatin for advanced esophagogastric cancer N Engl J Med 358 2008 36 46
7. W. Koizumi, H. Narahara, and T. Hara S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol 9 2008 215 221
8. Y.K. Kang, W.K. Kang, and D.B. Shin Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial Ann Oncol 20 2009 666 673
9. J.A. Ajani, W. Rodriguez, and G. Bodoky Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial J Clin Oncol 28 2010 1547 1553
10. Y.J. Bang, E. Van Cutsem, and A. Feyereislova Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 2010 687 697
11. A. Ohtsu, M.A. Shah, and E. Van Cutsem Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study J Clin Oncol 29 2011 3968 3976
12. E.D. Saad, A. Katz, and M. Buyse Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials J Clin Oncol 28 2010 1958 1962
13. F. Petrelli, and S. Barni Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer Ann Oncol 24 2013 186 192
14. H. Hayashi, I. Okamoto, and S. Morita Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer Ann Oncol 23 2012 1537 1541
15. K. Hotta, K. Kiura, and Y. Fujiwara Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review PLoS One 6 2011 e26646
16. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
17. B. Efron, and R.J. Tibshirani An introduction to the bootstrap 1993 Chapman and Hall/CRC New York
18. K.R. Johnson, C. Ringland, and B.J. Stokes Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis Lancet Oncol 7 2006 741 746
19. M. Buyse, D.J. Sargent, and A. Grothey Biomarkers and surrogate end points - the challenge of statistical validation Nat Rev Clin Oncol 7 2010 309 317
20. P.C. Thuss-Patience, A. Kretzschmar, and D. Bichev Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer-a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Eur J Cancer 47 2011 2306 2314
21. J.H. Kang, S.I. Lee, and H. Lim do Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone J Clin Oncol 30 2012 1513 1518
22. K. Shitara, J. Ikeda, and C. Kondo Reporting patient characteristics and stratification factors in randomized trials of systemic chemotherapy for advanced gastric cancer Gastric Cancer 15 2012 137 143
23. P.A. Tang, S.M. Bentzen, and E.X. Chen Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy J Clin Oncol 25 2007 4562 4568
24. K. Shitara, J. Ikeda, and T. Yokota Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials Invest New Drugs 30 2012 1224 1231
25. K.R. Broglio, and D.A. Berry Detecting an overall survival benefit that is derived from progression-free survival J Natl Cancer Inst 101 2009 1642 1649